- Home
- MDCX
as 05-09-2025 4:00pm EST
Stocks
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
| Founded: | 2008 | Country: | Canada |
| Employees: | N/A | City: | W. CONSHOHOCKEN |
| Market Cap: | 48.4M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 56.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $4.99 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicus Pharma Ltd. Common Stock News
MDCX Breaking Stock News: Dive into MDCX Ticker-Specific Updates for Smart Investing
Newsfile
11 days ago
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Newsfile
18 days ago
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Newsfile
2 months ago
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Newsfile
2 months ago
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Newsfile
2 months ago
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Newsfile
2 months ago
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
GlobeNewswire
2 months ago
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Newsfile
3 months ago
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Compare MDCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDCX Medicus Pharma Ltd. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.